## natraceutical

## Mr. Iñigo de la Lastra

Head of Secondary Markets
CNMV
Edison, 4
28006 Madrid
Valencia (Spain), September 30, 2014

## RELEVANT FACT

Dear Sir,

In accordance with Article 82 of Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, and in relation to the Relevant Fact dated September 22, 2014, and registration number 211055 by which Natraceutical SA convened an Extraordinary General Shareholders Meeting to approve the merger with Laboratorio Reig Jofre SA, the company informs about the following:

As stated in the documentation made available for the Shareholders' Meeting and, precisely, in relation to the conditions precedent which the merger is subject to, on September 10, 2014 the independent expert designated by the Commercial Registry of Valencia issued a favorable report on the method and rationale for fixing the exchange ratio as well as on the equivalence between the equity assets and liabilities contributed by Laboratorio Reig Jofre SA and the capital increase in Natraceutical SA to integrate Laboratorio Reig Jofre. Similarly, as of September 11, 2014, the Spanish Commission of Markets and Competition (CNMC) closed the file on the economic concentration of the merger.

As a result of the foregoing, Natraceutical SA informs that previous to the celebration of the Extraordinary General Shareholders Meeting, the CEOs of Natraceutical SA and Laboratorio Reig Jofre SA shall present the merger and other business details of the resulting company to the financial community, in the following events:

- Madrid Stock Exchange: Wednesday, October 15, 2014 at 12:30h
- Valencia Stock Exchange: Thursday, October 16, 2014 at 12:30h
- Barcelona Stock Exchange: Monday, October 20, 2014 at 12:30h

These presentations will be public and may be attended by the companies' shareholders, investors, analysts and media.

Yours faithfully,

Ma José Busutil Santos
Secretary of the Board of Directors
natraceutical

